XML 46 R37.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2020
Non current assets $ 1,900,000   $ 1,900,000   $ 1,700,000
Clinical service trial     12,000,000    
Cash paid related to finance leases     1,600,000    
Cash paid related to finance leases interest     900,000 $ 600,000  
Cash paid related to operating leases $ 64,000 $ 66,000 $ 176,000 198,000  
Weighted average discount rate 8.45%   8.45%    
Weighted average discount rate operating lease 10.20%   10.20%    
Interest rate 10.19%   10.19%   10.00%
Maturity years     7 years 3 months 18 days    
Operating lease maturity years     5 years 10 months 24 days    
Total cash paid related to finance leases $ 1,600,000.0   $ 1,600,000.0   $ 900,000.0
Net book value of the finance lease right of use asset 13,100,000   13,100,000   13,800,000
Balance of the finance lease liability 14,100,000.0   14,100,000.0   12,700,000.0
Current balance 500,000   500,000   900,000
Change in operating lease liability     22,459 (815)  
Operating lease - liability 1,100,000   1,100,000   1,300,000
Change in net loss     29,000    
Net book value operating lease right of use assets 1,000,000.0   1,000,000.0   1,200,000
Change in right of use of assets and liability     500,000    
Change in lease expense 27,000   27,000    
Change in operating lease right of use of assets     $ 712,000    
Balance of the operating lease liabilities         1,300,000.0
Weighted average time to maturity     5 years 10 months 24 days    
Operating lease expense 66,000 67,000 $ 200,000 200,000  
Finance lease liability 14,100,000   14,100,000   12,700,000
Research and development expenses     34,800,000    
Net of discount     $ 11,700,000    
Lease description     The revised rate upon adoption of ASC 842 was calculated to be 10.19% compared to the previously used rate of 8.80%, and the revised rate for the lease modification was calculated to be 8.45% compared to the previous rate of 10.00%.    
Finance lease obligations, net of current portion $ 200,000   $ 200,000   $ 100,000
Biologics License Application [Member]          
Sublease rental income   $ 2,000   39,000  
Ergomed [Member]          
Research and development expenses     $ 1,400,000 $ 1,300,000  
Landlord [Member]          
Interest rate 8.45%   8.45%    
Finance lease liability $ 1,600,000   $ 1,600,000    
Lease description     The repayment will include a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.    
Additional deposit $ 200,000   $ 200,000    
Cost incurred, initial     10,500,000    
Estimated cost     10,700,000    
Financing arrangement     $ 2,400,000